Login
Toggle sidebar

Lint: tumour-pseudoresponse

tumour-pseudoresponse
Adjectival Hyphens
error

"Typical features of pseudoresponse when compared to pre-treatment scans:"

Line 11:56 · Only use medical adjectival hyphens where the letters at the end and start of the compound word are the same, e.g. post-transplant. In this case, don't use the hyphen: 'pre-treatment'.
Emphasis
warning

"Tumour pseudoresponse, also known just as pseudoresponse, refers to the phenomenon of tumours appearing to respond to a specific treatment on imaging criteria when the lesion actually remains stable or has even progressed."

Line 1:94 · Italics should be used only in exceptional circumstances: '<em>,</em>'
Headings Valid
warning

Expected headings

  • H1 Terminology
  • H1 Usage
  • H1 Epidemiology
  • H2 Risk factors
  • H2 Associations
  • H1 Clinical presentation
  • H2 Complications
  • H1 Diagnosis
  • H2 Diagnostic criteria
  • H2 Diagnostic clues
  • H1 Pathology
  • H2 Aetiology
  • H2 Location
  • H2 Classification
  • H2 Macroscopic appearance
  • H2 Microscopic appearance
  • H2 Immunophenotype
  • H2 Markers
  • H2 Genetics
  • H1 Radiographic features
  • H2 Plain radiograph
  • H2 Mammography
  • H2 Antenatal ultrasound
  • H2 Transoesophageal echocardiography
  • H2 Ultrasound
  • H2 CT
  • H3 Dual-energy CT
  • H2 Angiography (DSA)
  • H2 MRI
  • H2 CT/MRI
  • H2 Nuclear medicine
  • H3 PET-CT
  • H3 PET-MRI
  • H1 Radiology report
  • H1 Treatment and prognosis
  • H2 Complications
  • H1 History and etymology
  • H1 Differential diagnosis
  • H2 Clinical differential diagnosis
  • H1 Practical points
  • H1 See also

"Coagulative necrosis"

Line 20:1 · "Coagulative necrosis" is not a recognised heading for this article type.
Oxford Comma
suggestion

"The term is largely used for brain tumours during imaging follow-up, especially for high-grade gliomas (e.g. glioblastoma) in which a rapid decrease in contrast enhancement and oedema can be observed in a short period of time after administration of antiangiogenic agents (e.g, bevacizumab and cediranib), often without any significant change in actual tumour size (as visualised on non-contrast sequences) or diffusion/perfusion studies 1-3."

Line 3:286 · Use the Oxford comma in 'g, bevacizumab and cediranib'.
Links
0
0
0
0
0
0
0
0
0
0
0
0